Pharming Group (NASDAQ:PHAR – Get Free Report) was the recipient of a large increase in short interest in October. As of October 15th, there was short interest totalling 9,100 shares, an increase of 122.0% from the September 30th total of 4,100 shares. Based on an average trading volume of 7,500 shares, the short-interest ratio is currently 1.2 days.
Analysts Set New Price Targets
Separately, HC Wainwright reissued a “buy” rating and issued a $37.00 price objective on shares of Pharming Group in a research report on Thursday.
Get Our Latest Stock Analysis on PHAR
Institutional Trading of Pharming Group
Pharming Group Trading Up 4.8 %
Shares of PHAR stock traded up $0.40 during mid-day trading on Friday, hitting $8.70. The company’s stock had a trading volume of 6,324 shares, compared to its average volume of 4,887. The company’s fifty day simple moving average is $8.05 and its 200-day simple moving average is $8.54. Pharming Group has a 52 week low of $6.65 and a 52 week high of $13.20. The company has a debt-to-equity ratio of 0.40, a quick ratio of 2.65 and a current ratio of 3.39. The company has a market cap of $590.12 million, a PE ratio of -45.79 and a beta of 0.15.
Pharming Group (NASDAQ:PHAR – Get Free Report) last issued its earnings results on Thursday, August 1st. The company reported ($0.01) EPS for the quarter. Pharming Group had a negative net margin of 4.65% and a negative return on equity of 5.69%. The firm had revenue of $74.09 million during the quarter, compared to the consensus estimate of $71.95 million. During the same period in the previous year, the firm earned $0.02 earnings per share. As a group, equities research analysts expect that Pharming Group will post -0.15 earnings per share for the current fiscal year.
Pharming Group Company Profile
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
See Also
- Five stocks we like better than Pharming Group
- Insider Trades May Not Tell You What You Think
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- What Are Dividend Contenders? Investing in Dividend Contenders
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- 3 Healthcare Dividend Stocks to Buy
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.